Full-Time

Senior Director

PV Case & Study Operations

Posted on 12/13/2025

Exelixis

Exelixis

1,001-5,000 employees

Biopharmaceutical oncology company developing cancer therapies

Compensation Overview

$262.5k - $373k/yr

+ Bonus + Equity incentives/stock options + Stock purchase plan

Alameda, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • BS/BA degree in related discipline and a minimum of fifteen years of related experience; or, MS/MA degree in related discipline and a minimum of thirteen years of related experience; or, PhD, MD, or PharmD in related discipline and a minimum of twelve years of related experience; or, Equivalent combination of education and experience.
  • Experience in Drug Safety and Pharmacovigilance including 8+ years of experience in Pharmacovigilance Operations.
  • Minimum of 7 years of line management experience overseeing PV staff and/or consultants/CROs.
  • Working knowledge of and experience with international regulatory Adverse Event Reporting requirements.
  • Proven experience and effectiveness at training and mentoring drug safety staff.
  • Extensive knowledge of biotechnology/pharmaceutical sector drivers and practices.
  • Demonstrated and excellent knowledge of relevant US and international regulations, guidance and initiatives governing both clinical trial and post-marketing safety environments.
  • Demonstrated advanced skill and keen insight in gathering, sorting and applying key information to solve problems.
  • Demonstrates strong organizational and planning capabilities by managing time, workload, and resources of a function.
  • Leads and manages a functional area within a department to execute on team functional objectives that contribute to accomplishing common functional and departmental goals.
  • Demonstrates high standards of verbal and written communication. Provides timely and appropriate information updates. Speaks clearly and confidently in one-to-one situations and effectively presents to audiences within and outside Exelixis.
  • Fosters collaboration among team members. Encourages teams to align on common goals. Engages internal and external stakeholders to build relationships.
  • Strong interpersonal skills and skilled at effectively resolving challenges by developing an agreed upon resolution.
  • Develops procedures, tasks, and tools. Trains staff on departmental products, tools, and data sources. Develops and maintains knowledge of cross-functional products, tools, and data sources. Mentors junior team members. Contributes to performance reviews and professional development plans of team members.
  • Capable of proactively assessing workload, trends, tasks, and priorities for cross-functional activity.
  • Plans and executes multiple projects or activities, considering alternative methods and contingency plans to avoid potential issues.
  • Designs and implements solutions to address cross functional project level challenges, taking into consideration the broader impact.
  • Engages, influences, and collaborates with stakeholders on cross-functional projects.
Responsibilities
  • Lead the global ICSR activities to comply with global ICSR regulations.
  • Manage and lead the team who prepares, processes, and performs reporting activities of SAE/SUSAR reports for all Exelixis investigational drugs.
  • Oversee processes, training and compliance of external case management vendors.
  • Ensure submission compliance with business partners, CROs and global regulatory authorities.
  • Provide oversight of ICSR regulatory submissions to ensure compliance with global regulations.
  • Ensure data reconciliation of the safety and clinical databases for Serious Adverse Events.
  • Effectively utilize metrics to assess productivity, opportunities for workflow and quality improvement, and to measure effectiveness of change initiatives.
  • Work with VP, Pharmacovigilance and other GPS colleagues to ensure PV compliance and inspection readiness.
  • Support data readiness for generation and submission of aggregate reports (e.g., DSUR, PBRER, and IDMC listings).
  • Collaborate with other GPS functions to ensure alignment among case management, aggregate reporting, and signal detection activities.
  • Collaborate with clinical teams in the preparation of and updates to safety-related study documents (e.g., Protocols, ICFs, Safety Management Plans).
  • Collaborate with the Quality Management function to develop or update Standard Operating Procedures and Work Instructions for GPS, which are integrated and fully aligned.
  • Significant cross-departmental interactions with other Exelixis functions, including Clinical Data Management, Clinical Operations, Clinical Development, and Quality Assurance groups.

Exelixis develops and commercializes medicines for cancer. Its products aim to treat advanced cancers, including renal cell carcinoma, by targeting multiple biological pathways and supporting combination regimens to achieve effective, tolerable, and durable responses. The company generates revenue from sales of approved therapies and strategic partnerships, backed by extensive research, clinical trials, and regulatory approvals to bring new drugs to market. Compared with peers, Exelixis focuses on a pipeline that combines multi-pathway targeting with combination therapies to improve patient outcomes. Its overall goal is to advance cancer treatment and offer patients better chances of remission through its ongoing drug development programs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • 2026 revenue guidance hits $2.53-$2.63 billion driven by Cabometyx $2.1 billion sales growth.
  • Zanzalintinib Phase 3 enrollment completes for non-clear cell RCC with H1 2026 data readout.
  • $750 million buyback supports stock after 97% five-year rise toward top-5 oncology status.

What critics are saying

  • Merck HIF-2alpha inhibitor erodes Cabometyx RCC share post-March 2026 data, dropping stock 5-10%.
  • 130 layoffs including 4 VPs disrupt zanzalintinib Phase 3 execution by Q4 2026.
  • King of Prussia closure triggers scientist exodus to Merck, halting ADC pipeline in 2027.

What makes Exelixis unique

  • Cabometyx dominates renal cell carcinoma with approvals in kidney, liver, thyroid cancers until 2031 generics.
  • Zanzalintinib advances in four Phase 3 trials post-FDA approval for metastatic colorectal cancer February 2026.
  • Pipeline features antibody-drug conjugates targeting GI and GU oncology precisely.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Company News

Insider Monkey
Mar 28th, 2026
RBC Capital lowers Exelixis (EXEL) price target to $43.

RBC Capital lowers Exelixis (EXEL) price target to $43. Published on March 28, 2026 at 3:18 am by venkatesh in news. On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm's Sector Perform rating was maintained on the stock. In a research note, RBC Capital pointed out that after the reporting of the data from the HIF-2alpha inhibitors study by Exelixis, Inc. (NASDAQ:EXEL)'s competitor Merck (MRK), the share value of the company will potentially witness a decline in the range of 5% to 10%, owing to competitive pressures. Separately, H.C. Wainwright raised its price target on Exelixis, Inc. (NASDAQ:EXEL) from $52 to $54 while maintaining a Buy rating on February 12, 2026. Analysts updated their model following the reporting of the results for the fourth quarter of 2025. As of March 25, 2026, Exelixis, Inc. (NASDAQ:EXEL) maintains a Buy rating from 45% of 22 analysts followed by CNN, with a 1-year average upside potential of 15.47%. Founded in 1994, Exelixis, Inc. (NASDAQ:EXEL) is a leading oncology-focused biotechnology company with headquarters in California. The company specializes in discovering and commercializing next-generation medicines like CABOMETYX to treat difficult-to-treat cancers. While we acknowledge the risk and potential of EXEL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EXEL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Yahoo Finance
Mar 16th, 2026
Exelixis posts $2.1B sales, eyes $2.4B guidance as zanzalintinib PDUFA nears

Exelixis outlined its commercial strategy and pipeline at a Barclays conference, with Senior Vice President Andrew Peters highlighting CABOMETYX as the company's commercial foundation. The lead product, cabozantinib, holds approvals across kidney, liver, thyroid cancer and neuroendocrine tumours. The company reported $2.123 billion in net product sales last year and has guided to approximately $2.4 billion for this year. Growth is expected from continued strength in renal cell carcinoma and the neuroendocrine tumour launch. Peters described Exelixis as a "big small company" focused on GI and GU oncology, with disciplined business development guided by a "Cabo lens" framework. The company is advancing zanzalintinib, a next-generation tyrosine kinase inhibitor, alongside broader pipeline development in small molecules and biotherapeutics.

Yahoo Finance
Mar 1st, 2026
Exelixis targets top 5 oncology status with growing pipeline and $750M buyback

Exelixis, a biotech company aiming to become a top-five solid tumour oncology company, has seen its shares rise over 20% in the past year and 97% over five years. The company's growth is driven by three key factors. Its blockbuster drug cabozantinib continues expanding indications, treating kidney, thyroid, liver and pancreatic cancers, with generic competition not expected until early 2031. In 2025, revenue rose 7% to $2.3 billion, whilst earnings per share increased 57.9% to $2.78. Zanzalintinib, approved by the FDA in February for metastatic colorectal cancer, is currently in four phase 3 trials for various cancer types. The company's pipeline also includes promising antibody-drug conjugates that precisely target cancer cells.

Yahoo Finance
Jan 20th, 2026
Exelixis gets mixed analyst calls as zanzalintinib nears 2026 launch, targets $2.6B revenue

Exelixis saw mixed analyst actions on 8 January as its cancer drug zanzalintinib approaches commercial launch. H.C. Wainwright raised its price target to $52 from $49, maintaining a Buy rating, citing investor sentiment around zanzalintinib's commercial potential as a key near-term value driver. However, Morgan Stanley downgraded the stock to Equal Weight from Overweight, raising its price target to $48 from $45. The firm noted the stock had risen roughly 28% over the prior year and now trades barely 10% below the updated target. On 11 January, Exelixis reported preliminary 2025 revenues of approximately $2.32 billion and forecast 2026 sales of $2.525–$2.625 billion. Zanzalintinib is expected to launch commercially for multiple cancer indications in 2026.

ADVFN
Jan 1st, 2026
Exelixis Regains Full Rights to Develop and Commercialize XL184

Exelixis regains full rights to develop and commercialize XL184. Exelixis, Inc. (Nasdaq:EXEL) today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS' wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the ongoing clinical development of XL184. As a result, BMS returned XL184 to Exelixis, thereby giving Exelixis the opportunity to advance the program as originally envisioned. BMS will make a payment to Exelixis of $17 million in connection with the return of XL184. "We believe in the clinical and commercial potential of XL184 in a broad array of cancer indications. The data that we recently presented at ASCO were encouraging," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We certainly understand BMS' need to make pipeline and prioritization decisions, but from Exelixis' perspective, XL184 is our most advanced compound, the data are encouraging, and we need to rapidly develop the compound in indications justified by the data, including medullary thyroid cancer, glioblastoma, and potentially some of the major tumor types being evaluated in the randomized discontinuation trial. We regret BMS' decision, but we are pleased to now have the opportunity to develop XL184 independent of divergent pipeline and portfolio considerations. It is a sign of the strength of our relationship that we could achieve this outcome for XL184 at the same time that we continue our positive collaborations around a number of other compounds. We have the resources to take XL184 forward on our own for some time and we see several attractive longer term options, which we are currently evaluating." XL184 Clinical Development Program XL184 is currently being evaluated in 13 tumor types across multiple clinical trials. As recently reported at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) in early June, in an expanded cohort in phase 1 of patients with medullary thyroid cancer, XL184 demonstrated a 29% response rate, with a median duration of response that had not yet been reached, with a range of 4 to 35+ months. XL184 is currently being evaluated in a pivotal phase 3 clinical trial in patients with medullary thyroid cancer. Assuming positive results from the pivotal trial, Exelixis anticipates submitting a new drug application (NDA) with the Food and Drug Administration for XL184 in this indication in 2011. Also as reported at the 2010 ASCO Annual Meeting, in a phase 2 clinical trial in patients with recurrent glioblastoma, XL184 demonstrated a 30% response rate when dosed at 125 mg daily, with a median duration of response of 5.1 months. Exelixis expects to initiate a phase 3 pivotal trial in recurrent glioblastoma in the year-end 2010 time frame. In addition, as reported at the 2010 ASCO Annual Meeting, objective responses with XL184 have been observed in patients with refractory melanoma, non-small cell lung cancer (NSCLC) (both as a single agent and in combination with erlotinib), hepatocellular carcinoma, prostate and ovarian cancers in an ongoing adaptive randomized discontinuation trial (RDT). Exelixis expects to prioritize tumor types from the RDT for further development early in 2011. The detailed safety and efficacy data regarding XL184 reported at the 2010 ASCO Annual Meeting are available in the four XL184 press releases issued by Exelixis on May 20, 2010, which are available under "Investors" on Exelixis' website, www.exelixis.com. About XL184 XL184 is an investigational oral inhibitor of MET, VEGFR2, and RET that produces antiangiogenic, antiproliferative, and antiinvasive effects in preclinical tumor models. MET is mutationally activated in some tumor types, such as hereditary and sporadic papillary renal cell carcinoma and some head and neck cancers. More frequently, MET is either over-expressed or activated in the absence of mutation in glioblastomas, breast carcinomas, some gastric cancers, and other solid tumors. MET amplification has been demonstrated in some NSCLCs. Expression of VEGF has been observed in a variety of cancers and has been associated with prognostic significance. Targeting the VEGF receptor has been recognized as a potential anti-cancer strategy in multiple tumors. Dual targeting of MET and VEGFR2 blocks two of the major mechanisms tumors use to overcome hypoxia. Activated RET is involved in cell signaling cascades that regulate cell proliferation, migration, differentiation, and survival. RET is mutationally activated in papillary thyroid cancer (PTC) and in both familial and sporadic forms of medullary thyroid cancer (MTC). About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com. This press release contains forward-looking statements, including, without limitation, all statements related to the future clinical development of and regulatory submissions with respect to XL184 and other Exelixis compounds (including the timing thereof), the clinical, therapeutic and commercial potential of XL184, the receipt of $17 million from BMS, the sufficiency of Exelixis' financial and other resources to take XL184 forward on its own for some time and Exelixis' ability to execute longer term options for financing the XL184 development program. Words such as "expects," "will," "potential," "opportunity," "anticipates" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the sufficiency of Exelixis' capital, including risks related to satisfaction by Exelixis of its obligations under its loan from GlaxoSmithKline, the risk that the closing of the previously announced transaction with Deerfield will not occur on the anticipated timing, or at all, due to potential failure to satisfy the conditions to closing, and the risk that if additional capital is not available to Exelixis, it would be forced to delay, reduce or eliminate its product development programs efforts and may breach its financial covenants; the potential failure of XL184 and other Exelixis compounds to demonstrate safety and efficacy in future clinical testing; Exelixis' dependence on current and anticipated future collaborations; Exelixis' ability to conduct clinical trials for its compounds sufficient to achieve a positive completion; regulatory approval of and competition related to Exelixis' compounds and the uncertain timing and level of expenses associated with the development of Exelixis' programs. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended April 2, 2010 and other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any duty, obligation, or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Exelixis (NASDAQ:EXEL)

INACTIVE